Abstract
Genetic, immune and environmental interactions are key elements for the development of COPD. Cigarette smoking is considered the primary risk factor initiating inflammatory cascades in genetically susceptible individuals.
The “danger signals” elicited by the injured cells of non-specific immunity induce the downstream activation of proinflammatory cascades and antigen-specific adaptive immune responses. The produced oxidative stress further damages the lung leading to acquired genetic changes (histone deacetylation, microsatellite DNA instability, DNA methylation, telomere shortening, miRNA alterations) due to an inefficient DNA repair machinery. On the other hand, augmented apoptosis, impaired efferocytosis and abnormal tissue remodeling contribute to the chronic inflammatory response and tissue destruction in COPD.
This review focuses on the role of genetic, epigenetic and immune mechanisms in the development of COPD in order to put forward possible prognostic and therapeutic targets.
Keywords: Adaptive immunity, chronic inflammation, chronic obstructive pulmonary disease, DNA damage, epigenetics, innate immunity, oxidative stress
Current Drug Targets
Title:Immune and Genetic Mechanisms in COPD: Possible Targets for Therapeutic Interventions
Volume: 14 Issue: 2
Author(s): Eleni G. Tzortzaki, Alberto Papi, Eirini Neofytou, Nikolaos Soulitzis and Nikolaos M. Siafakas
Affiliation:
Keywords: Adaptive immunity, chronic inflammation, chronic obstructive pulmonary disease, DNA damage, epigenetics, innate immunity, oxidative stress
Abstract: Genetic, immune and environmental interactions are key elements for the development of COPD. Cigarette smoking is considered the primary risk factor initiating inflammatory cascades in genetically susceptible individuals.
The “danger signals” elicited by the injured cells of non-specific immunity induce the downstream activation of proinflammatory cascades and antigen-specific adaptive immune responses. The produced oxidative stress further damages the lung leading to acquired genetic changes (histone deacetylation, microsatellite DNA instability, DNA methylation, telomere shortening, miRNA alterations) due to an inefficient DNA repair machinery. On the other hand, augmented apoptosis, impaired efferocytosis and abnormal tissue remodeling contribute to the chronic inflammatory response and tissue destruction in COPD.
This review focuses on the role of genetic, epigenetic and immune mechanisms in the development of COPD in order to put forward possible prognostic and therapeutic targets.
Export Options
About this article
Cite this article as:
G. Tzortzaki Eleni, Papi Alberto, Neofytou Eirini, Soulitzis Nikolaos and M. Siafakas Nikolaos, Immune and Genetic Mechanisms in COPD: Possible Targets for Therapeutic Interventions, Current Drug Targets 2013; 14 (2) . https://dx.doi.org/10.2174/1389450111314020002
DOI https://dx.doi.org/10.2174/1389450111314020002 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry Role of Monitoring Thiopurine Methyltransferase (TPMT) Activity in the Individualized Therapy with Azathioprine or 6-Mercaptopurine
Current Pharmacogenomics and Personalized Medicine Large Scale Preparation of the Mammalian High Mobility Group Protein A2 for Biophysical Studies
Protein & Peptide Letters Perspectives in Nanomedicine-Based Research Towards Cancer Therapies
Current Nanoscience Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of DNA Methyltransferases: Insights from Computational Studies
Current Medicinal Chemistry Subject Index to Volume 4
Current Medicinal Chemistry - Anti-Cancer Agents Cytostatic and Cytotoxic Activity of Synthetic Diterpene Derivatives Obtained from (-)-Kaur-9(11), 16-Dien-19-Oic Acid Against Human Cancer Cell Lines
Letters in Drug Design & Discovery Approaches to the Pharmacological Modulation of Plasmacytoid Dendritic Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Bisphosphonate Osteonecrosis (BON): Unanswered Questions and Research Possibilities
Reviews on Recent Clinical Trials Cytotoxic Nucleoside Analogues: Different Strategies to Improve their Clinical Efficacy
Current Medicinal Chemistry A Role for SHIP in Stem Cell Biology and Transplantation
Current Stem Cell Research & Therapy Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
Current Medicinal Chemistry Anti-VEGF Anticancer Drugs: Mind the Hypertension
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Older and New Formulations of Cladribine. Pharmacology and Clinical Efficacy in Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics MicroRNAs in Platelet Biogenesis and Function: Implications in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology New Strategies in the Discovery of Novel Non-Camptothecin Topoisomerase I Inhibitors
Current Medicinal Chemistry The Sodium-Iodide Symporter
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling
Current Gene Therapy